Publications by authors named "Chengxu Cui"

Claim this Profile
A
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.
Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Chengxu Cui

Eur J Med Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma.
Yan-Xing Chen, Zi-Xian Wang, Ying Jin, Qi Zhao, Ze-Xian Liu, Chengxu Cui

Cancer Cell· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.
Zi-Xian Wang, Chengxu Cui, Jun Yao, Yanqiao Zhang, Mengxia Li

Cancer Cell· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promising Immunotherapy in Metastatic Testicular Sex Cord Stromal Tumours After First-Line Chemotherapy.
Bingqing Shang, Chuanzhen Cao, Weixing Jiang, Hongzhe Shi, Xingang Bi, Chengxu Cui

Front Immunol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Lei Yang, Tongjian Cui, Chengxu Cui

Nat Commun· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial.
Shukui Qin, Feng Bi, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Chengxu Cui

J Clin Oncol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Real-World Practice of Fruquintinib for Chinese Patients with Metastatic Colorectal Cancer.
Yan Song, Tao Qu, Honggang Zhang, Yongkun Sun, Chengxu Cui

Cancer Manag Res· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
Ping Liang, Lijuan Qi, Taiyan Guo, Xia You, Chengxu Cui

Lung Cancer· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Zhichao Jiang, Yongkun Sun, Wen Zhang, Chengxu Cui, Lin Yang

Asia Pac J Clin Oncol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study.
Yue Yu, Jianming Ying, Wen Zhang, Weihua Li, Yongkun Sun, Chengxu Cui

Asia Pac J Clin Oncol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nab-paclitaxel plus S-1 as first-line followed by S-1 maintenance for advanced pancreatic adenocarcinoma: a single-arm phase II trial.
Wen Zhang, Chunxia Du, Yongkun Sun, Lin Yang, Chengxu Cui

Cancer Chemother Pharmacol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
UGT1A1*6, UGT1A7*3 and UGT1A9*1b polymorphisms are predictive markers for severe toxicity in patients with metastatic gastrointestinal cancer treated with irinotecan-based regimens.
Chengxu Cui, Chang Shu, Dandan Cao, Yi Yang, Junbao Liu

Oncol Lett· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index and age are additional prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Yan Song, Chunxia Du, Wen Zhang, Yongkun Sun, Lin Yang, Chengxu Cui

Urol Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma.
Yan Song, Chunxia Du, Wen Zhang, Yongkun Sun, Lin Yang, Chengxu Cui

Asia Pac J Clin Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy.
Yan Song, Chun-Xia Du, Wen Zhang, Yong-Kun Sun, Lin Yang, Cheng-Xu Cui

Chin Med J (Engl)· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer.
Chengxu Cui, Chang Shu, Yi Yang, Junbao Liu, Shuping Shi

Oncol Lett· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-labeled, randomized, multicenter phase IIa study of gambogic acid injection for advanced malignant tumors.
Yihebali Chi, Xiao-kai Zhan, Hao Yu, Guang-ru Xie, Zhen-zhong Wang, Cheng-xu Cui

Chin Med J (Engl)· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Phase II clinical trial of docetaxel, platinum and S-1 for advanced gastric cancer].
Ai-ping Zhou, Yu-sheng Li, Lin Yang, Yan Song, Yong-kun Sun, Cheng-xu Cui

Zhonghua Yi Xue Za Zhi· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma.
Yihebali Chi, Jian-Hong Ren, Lin Yang, Cheng-Xu Cui, Jun-Ling Li

Chin Med J (Engl)· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Ling-di Zhao, Jun-ling Li, Yan Wang, Bin Wang, Hong-yu Wang, Cheng-xu Cui

Zhonghua Zhong Liu Za Zhi· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Analysis of chemotherapeutic efficacy after a failed regimen of epidermal growth factor receptor-tyrosine kinase inhibitor in patients with advanced non-small cell lung carcinoma].
Ling-di Zhao, Jun-Ling Li, Yan Wang, Bin Wang, Hong-Yu Wang, Cheng-Xu Cui

Zhonghua Yi Xue Za Zhi· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis